Where does Janssen Vaccines & Prevention B.V. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Janssen Vaccines & Prevention B.V. ranks #3,282 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Janssen Vaccines & Prevention B.V. hold?

Janssen Vaccines & Prevention B.V. holds 114 US utility patents granted between 2016 and 2025, spanning 12 technology areas.

What is Janssen Vaccines & Prevention B.V.'s Innovation Score?

Janssen Vaccines & Prevention B.V. has an Innovation Score of 44.1 out of 100 (top 26% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Janssen Vaccines & Prevention B.V.'s patent grant rate increasing or decreasing?

Janssen Vaccines & Prevention B.V.'s recent grant velocity is +73% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Janssen Vaccines & Prevention B.V.'s patents?

Janssen Vaccines & Prevention B.V.'s patents average 19.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Janssen Vaccines & Prevention B.V. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Janssen Vaccines & Prevention B.V.

Q: What technology areas does Janssen Vaccines & Prevention B.V. focus on?

Janssen Vaccines & Prevention B.V.'s top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 99 patents. Grants appear in 12 CPC subclasses total.

USPTO PatentsView assignee record - 114 granted patents across 12 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Janssen ranks #3,282 of 49,997 tracked US assignees by granted-patent volume, with 114 patents across 12 technology areas.

#3,282
of 49,997 US assignees by volume: Top 26%
by Innovation Score (44.1/100): 19.1
avg claims per patent: +73%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R3282 · Foreign Corporation #3,282 · 114 grants

GRANTS-MID · TOP-DECILE · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MID 114 grants
TOP-DECILE #3,282/49,997
PHOTO-FINISH Exfo
CPC-FOCUS A61K · 12 areas
INNOV-PAR 44.1/100
CLAIMS-RICH 19.1 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +73% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Exfo Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Globalfoundries U S 2 · near

44
Janssen Vaccines &… · this assignee

44
Johannes Gutenberg-U… · near

44
LiveArena AB · near

44
Roche Diagnostics… · near

44
3D Lighting… · lowest

7

What this shows Janssen's Innovation Score is 44.1/100 (top 26% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Janssen's grants concentrate

Janssen Vaccines & Prevention B.V. is a focused PatentsView assignee: 12 CPC subclasses with 86.8% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2019 (22 grants) versus a trough of 4 in 2016. By volume, Janssen sits between Exfo Inc. and Maschinenfabrik Rieter AG.

Janssen's three-year grant acceleration

From 2019–2021 to 2022–2024, Janssen Vaccines & Prevention B.V. moved from 58 to 35 grants (0.60x the prior three-year total, a multiple, not a CAGR). Among 3,296 tracked assignees with ≥100 grants and ≥20 prior-period grants, that multiple ranks #2,438. See the growth leaderboard.

Exfo

114
Hiroshima Univers…

114
Hankook Tire

114
Hong Kong Baptist…

114
F C C

114
Kymeta

114
Miele & CIE KG

114
Maschinenfabrik R…

114
Janssen Vaccines… ◀

114

What this shows Janssen holds 114 patents at rank #3,282, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Janssen

By rank, the assignees closest to #3,282 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in Janssen's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Janssen, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (44 here).

Globalfoundries U.S. 2 LLC 44 Roche Diagnostics International AG 44 Johannes Gutenberg-Universität Mainz 44 LiveArena Technologies AB 44

Similar claim depth

Nearest assignees by average claims per patent (19.1 here).

Moxtek, Inc. 19.1 avg Enlitic, Inc. 19.1 avg Fisher Controls International LLC 19.1 avg Velodyne Lidar USA, Inc. 19.1 avg

Janssen's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

44 Top 26% higher than 74% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table

Janssen Vaccines & Prevention B.V. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2016	4	3.5%
2017	5	4.4%
2018	10	8.8%
2019	22	19.3%
2020	16	14.0%
2021	20	17.5%
2022	18	15.8%
2023	9	7.9%
2024	8	7.0%
2025partial year	2	1.8%

Which technologies does Janssen Vaccines & Prevention B.V. patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 99

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 93

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 93

C07K - Peptides 82

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 19

Y02A - Technologies FOR Adaptation TO Climate Change 10

C07D - Heterocyclic Compounds 1

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 1

C40B - Combinatorial CHEMISTRY; Libraries, e.g. Chemical Libraries 1

G16B - Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology 1

G16C - Computational CHEMISTRY; CHEMOINFORMATICS; Computational Materials Science 1

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 1

Top 12 of 12 technology areas

Where it ranks

Overall rank by patents

#3,282

of 49,997 tracked assignees

Innovation Score

44.1 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Janssen Vaccines & Prevention B.V.'s patent record in context - here's where to go next.

Janssen Vaccines & Prevention B.V.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 86.8% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #3,282 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Janssen Vaccines & Prevention B.V. against Exfo Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 44.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.